All In Biotech

Drug Trial Radar · NCT06970847

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

May 16, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Clarity Pharmaceuticals LtdIndustry
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Conditions

  • Prostate Cancer
  • Prostate Cancer Patients With Detectable PSA Following Prostatectomy
  • Prostate Cancer Recurrent
  • Prostate Cancer Patients Who Have Brachytherapy Seed Implant
  • Prostate Cancer Patients Treated by Radiotherapy
  • Cryotherapy

Interventions

  • 64Cu-SAR-bisPSMADrug

    All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancerTime frame: Up to 52 Weeks

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • UC Irvine

    Irvine, California

  • Comprehensive Urology Medical Group

    Los Angeles, California

  • Alarcon Urology Center

    Montebello, California

  • Biogenix Molecular

    Miami, Florida

  • Endeavor Health- Glenbrook Hospital

    Glenview, Illinois

  • Indiana University Health-IU Simon Cancer Center

    Indianapolis, Indiana

  • XCancer Research Network / LCMC Health EJGH

    Metairie, Louisiana

  • M. Health Fairview University of Minnesota Medical Center

    Minneapolis, Minnesota

  • St. Louis University

    St Louis, Missouri

  • XCancer

    Omaha, Nebraska

  • Albany Medical College

    Albany, New York

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Urology Associates, P.C.

    Nashville, Tennessee

  • Urology Clinics of North Texas

    Dallas, Texas

  • The Urology Place

    San Antonio, Texas

  • Summit Urology

    Murray, Utah

  • Intermountain Medical Center

    Salt Lake City, Utah

  • St. Vincent's Hospital, Sydney

    Darlinghurst, New South Wales, Australia

  • Sydney Adventist Hospital

    Wahroonga, New South Wales, Australia

  • Westmead Private Hosptial

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.